Natco Pharma Ltd

BSE: 524816

45

total announcements

NATCOPHARM.NS · 15 min delayed

Key Stats · Yahoo Finance · as of 19 Nov 2026

Market Cap

₹16,098 Cr

P/E (TTM)

17.9

P/E (Forward)

17.5

EPS (TTM)

₹45.89

52W Low

₹773.60

52W High

₹1,226.80

Dividend Yield

0.54%

Beta

0.18

Price / Book

1.5

Return on Equity

9.01%

Debt / Equity

10.6

Revenue (TTM)

₹3,092 Cr

Gross Margin

78.56%

Operating Margin

18.32%

BSECompany Update▲ PositiveFundraise28 Sept 2026

Natco Pharma Ltd

Press Release and disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

Natco Pharma Ltd has increased its investment in eGenesis, Inc. from $14 million to $16.70 million through its wholly owned subsidiaries. eGenesis is a biotechnology company focused on using its multiplex gene editing and genome engineering platform to transform solid organ and therapeutic cell transplantation for the treatment of serious diseases.

Read more →📎 1 attachment
BSECompany UpdateFundraise26 Sept 2026

Natco Pharma Ltd

Newspaper Publication of Record date for Rights Issue

Natco Pharma Ltd has published a newspaper advertisement announcing the record date for its rights issue, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Read more →📎 1 attachment
BSECorp. ActionFundraise25 Sept 2026

Natco Pharma Ltd

Intimation of Record Date for Rights Issue

Natco Pharma Ltd has announced the record date for its rights issue, set as Thursday, 1st October, 2026, to determine the shareholders eligible to receive the rights entitlements.

Read more →📎 1 attachment
BSECompany UpdateFundraise25 Sept 2026

Natco Pharma Ltd

Out come of Board Meeting

Natco Pharma Ltd has announced the outcome of its Board Meeting, where it has approved the issuance of equity shares through a rights issue to eligible equity shareholders. The rights issue will be for an amount not exceeding ₹12,79,35,61,500 and will be priced at ₹750 per rights equity share.

Read more →📎 1 attachment
BSEBoard MeetingFundraise25 Sept 2026

Natco Pharma Ltd

Natco Pharma Limited has informed the Exchange that Board of Directors at its meeting held on September 25, 2026, has decided to issue equity shares on rights basis in the ratio of 2 : 21, i.e 2 Equity Shares for every 21 Equity Shares held at an Issue Price of Rs. 750 per share (including a premium of Rs. 748/- (Rupees Seven Hundred and Forty Eight only) per Rights Equity Share)

Natco Pharma Ltd has informed the Exchange that its Board of Directors has decided to issue equity shares on rights basis in the ratio of 2:21, with an issue price of Rs. 750 per share, for an amount not exceeding Rs. 12,79,35,61,500.

Read more →📎 1 attachment
BSEBoard MeetingFundraise22 Sept 2026

Natco Pharma Ltd

Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/09/2026 ,inter alia, to consider and approve to consider, discuss and decide various matters in connection with the Rights Issue, including the specific terms of the Rights Issue, such as the determination of the Rights Issue price and related payment mechanism, rights entitlement ratio, the record date and timing of the Rights Issue

Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 25/09/2026 to consider and approve the specific terms of the Rights Issue, including the determination of the Rights Issue price and related payment mechanism.

Read more →📎 1 attachment
BSECompany Update2 Sept 2026

Natco Pharma Ltd

Investor Meet

Natco Pharma Ltd has announced an investor meet on September 7, 2026, in Hyderabad, where company officials will interact with investors. The meeting schedule is subject to change.

Read more →📎 1 attachment
BSECompany Update▲ Positiveinvestment25 Aug 2026

Natco Pharma Ltd

Press Release & Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 regarding the investment in eGenesis, Inc.

Natco Pharma Limited has invested US$ 14 million in eGenesis, Inc. through convertible promissory notes, taking its total investment to US$ 22 million. eGenesis is a biotechnology company focused on using its multiplex gene editing and genome engineering platform to transform solid organ and therapeutic cell transplantation for the treatment of serious diseases.

Read more →📎 1 attachment
BSECompany UpdateMgmt Change24 Aug 2026

Natco Pharma Ltd

Intimation of Investor Meet

Natco Pharma Ltd has announced an investor meet, where company officials will participate in discussions with investors. The meet will be held on various dates in August 2026, and the company's latest investor presentation is available on its website.

Read more →📎 1 attachment
BSECompany UpdateMgmt Change19 Aug 2026

Natco Pharma Ltd

Investor Meet

Natco Pharma Ltd announced an investor meet on August 24, 26, and 27, 2026, in Singapore, organized by Nuvama Wealth Management and ICICI Securities Limited. The company's officials will participate in the meeting to discuss the latest investor presentation, available on the company's website.

Read more →📎 1 attachment
BSECompany Update19 Aug 2026

Natco Pharma Ltd

Investor Presentation

Natco Pharma Ltd has made an investor presentation, which is a general background information about the company's activities as of the date of the presentation.

Read more →📎 1 attachment
BSECompany UpdateResults14 Aug 2026

Natco Pharma Ltd

Investor Presentation for the Q1FY27

Natco Pharma Ltd has released its Q1FY27 Earnings Presentation, providing general background information about the company's activities as of the date of the presentation.

Read more →📎 1 attachment